New protease inhibitor granted FDA approval
New protease inhibitor granted FDA approval
The Food and Drug Administration has approved a liquid formulation of the HIV-1 protease inhibitor Agenerase (amprenivar) by Vertex Pharmaceuticals/Glaxo Wellcome. The approval is aimed at expanding the use of the drug for pediatric patients by promoting easier administration of combination therapies.
The drug originally was approved in a solid form in April of this year. The new approval comes with recommended pediatric doses of 22.5 mg/kg twice daily or 17 mg/kg three times daily (for patients 4 to 12 years old or up to 16 if weighing less than 50 kg). The capsule and oral formulations are not interchangeable on a milligram-per-milligram basis.
The drug is available in grape, bubblegum, and peppermint flavors in 240 ml bottles (15 mg/ml) at a wholesale price of $25.20.
[For more information, contact Glaxo Wellcome at (919) 483-8580.]
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.